Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 05/12/21
End: 02/10/23
Due: 02/10/24
Phase: N/A
Priority: Normal
Start: 06/12/19
End: 09/29/22
Due: 09/29/23
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid Tumors | NCT04886271 | Waterstone Hanxbio Pty Ltd | user2@example.com | None | 2021-05-12 | 2023-02-10 | 2024-02-10 | - | - | 2025-07-14 |
| The Safety, Tolerability, and Initial Efficacy of HX009 in Patients With Advanced Malignancies | NCT04097769 | Waterstone Hanxbio Pty Ltd | user2@example.com | None | 2019-06-12 | 2022-09-29 | 2023-09-29 | - | - | 2025-07-14 |